A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization
Veeva Systems (NYSE: VEEV) announced growing adoption of Veeva Compass Patient, their anonymous patient longitudinal data solution. The platform provides unlimited access to daily data, covering both retail and specialty brands, helping commercial teams optimize patient journey analysis, market sizing, and field force activation.
The Compass data network encompasses over 300 million U.S. patients, 3+ million healthcare providers and clinicians, 80+ billion prescription and medical records, and more than seven years of patient history. Bayer has implemented the solution across multiple brands, reporting enhanced ability to identify HCPs and patients compared to traditional sources.
The Veeva Compass Suite includes Prescriber and National modules, offering projected prescriptions and procedures data at various levels, and is part of the broader Veeva Data Cloud platform.
Veeva Systems (NYSE: VEEV) ha annunciato un crescente utilizzo di Veeva Compass Patient, la loro soluzione di dati longitudinali anonimi per i pazienti. La piattaforma offre accesso illimitato a dati quotidiani, coprendo sia i marchi al dettaglio che quelli specializzati, aiutando i team commerciali a ottimizzare l'analisi del percorso del paziente, la valutazione del mercato e l'attivazione della forza vendita.
Il network di dati Compass comprende oltre 300 milioni di pazienti negli Stati Uniti, più di 3 milioni di fornitori di assistenza sanitaria e clinici, oltre 80 miliardi di ricette e documenti medici, e più di sette anni di storia del paziente. Bayer ha implementato la soluzione su più marchi, segnalando una maggiore capacità di identificare HCP e pazienti rispetto alle fonti tradizionali.
La Veeva Compass Suite include moduli per prescrittori e nazionali, offrendo dati proiettati su prescrizioni e procedure a vari livelli, ed è parte della più ampia piattaforma Veeva Data Cloud.
Veeva Systems (NYSE: VEEV) anunció una creciente adopción de Veeva Compass Patient, su solución de datos longitudinales anónimos de pacientes. La plataforma proporciona acceso ilimitado a datos diarios, cubriendo tanto marcas de venta al por menor como especializadas, ayudando a los equipos comerciales a optimizar el análisis del recorrido del paciente, la evaluación del mercado y la activación de la fuerza de ventas.
La red de datos Compass abarca más de 300 millones de pacientes en EE.UU., más de 3 millones de proveedores de atención médica y clínicos, más de 80 mil millones de recetas y registros médicos, y más de siete años de historia del paciente. Bayer ha implementado la solución en varias marcas, reportando una mayor capacidad para identificar HCP y pacientes en comparación con fuentes tradicionales.
La Veeva Compass Suite incluye módulos de Prescriptores y Nacionales, ofreciendo datos proyectados sobre recetas y procedimientos a diversos niveles, y forma parte de la plataforma más amplia Veeva Data Cloud.
Veeva Systems (NYSE: VEEV)는 환자의 익명 장기 데이터 솔루션인 Veeva Compass Patient의 사용이 증가하고 있음을 발표했습니다. 이 플랫폼은 소매 및 전문 브랜드를 포함한 일일 데이터에 무제한으로 접근할 수 있도록 하여 상업 팀이 환자 여정 분석, 시장 규모 평가 및 현장 활성화를 최적화하는 데 도움을 줍니다.
Compass 데이터 네트워크는 미국 내 3억 명 이상의 환자, 300만 명 이상의 의료 제공자 및 임상의, 800억 건 이상의 처방전 및 의료 기록, 그리고 7년 이상의 환자 기록을 포함합니다. Bayer는 여러 브랜드에 걸쳐 이 솔루션을 구현하여 전통적인 소스에 비해 HCP 및 환자를 식별하는 능력이 향상되었다고 보고했습니다.
Veeva Compass Suite에는 주치의 및 국가 모듈이 포함되어 있으며, 다양한 수준에서 예측된 처방전 및 절차 데이터를 제공합니다. 또한, Veeva Data Cloud 플랫폼의 일환입니다.
Veeva Systems (NYSE: VEEV) a annoncé une adoption croissante de Veeva Compass Patient, leur solution de données longitudinales anonymes pour les patients. La plateforme offre un accès illimité à des données quotidiennes, couvrant à la fois les marques de détail et spécialisées, aidant les équipes commerciales à optimiser l'analyse du parcours des patients, l'évaluation du marché et l'activation de la force de vente.
Le réseau de données Compass comprend plus de 300 millions de patients aux États-Unis, plus de 3 millions de fournisseurs de soins de santé et cliniciens, plus de 80 milliards de prescriptions et dossiers médicaux, et plus de sept ans d'historique des patients. Bayer a mis en œuvre la solution sur plusieurs marques, signalant une capacité améliorée à identifier les HCP et les patients par rapport aux sources traditionnelles.
La Veeva Compass Suite inclut des modules Prescripteur et National, offrant des données projetées sur les prescriptions et procédures à divers niveaux, et fait partie de la plateforme plus large Veeva Data Cloud.
Veeva Systems (NYSE: VEEV) hat eine wachsende Akzeptanz von Veeva Compass Patient bekannt gegeben, ihrer anonymen longitudinalen Datenlösung für Patienten. Die Plattform bietet unbegrenzten Zugang zu täglichen Daten, die sowohl Einzelhandels- als auch Spezialmarken abdecken, und hilft den Vertriebsteams, die Analyse des Patientenpfades, die Marktgröße und die Aktivierung des Außendienstes zu optimieren.
Das Compass-Datennetzwerk umfasst über 300 Millionen US-Patienten, mehr als 3 Millionen Gesundheitsdienstleister und Kliniker, über 80 Milliarden Verschreibungen und medizinische Aufzeichnungen sowie mehr als sieben Jahre Patientengeschichte. Bayer hat die Lösung bei mehreren Marken implementiert und berichtet von einer verbesserten Fähigkeit, HCPs und Patienten im Vergleich zu traditionellen Quellen zu identifizieren.
Die Veeva Compass Suite umfasst Module für Verordner und National, bietet projizierte Verschreibungs- und Verfahrensdaten auf verschiedenen Ebenen und ist Teil der umfassenderen Veeva Data Cloud-Plattform.
- Access to extensive data network covering 300M+ patients and 80B+ medical records
- Growing adoption by major pharmaceutical companies like Bayer
- Comprehensive coverage of both retail and specialty brands
- Unlimited data access at brand level
- None.
Insights
Veeva's Compass Patient platform represents a significant advancement in healthcare data analytics, offering biopharma companies unprecedented access to comprehensive patient and healthcare provider data. The platform's coverage of 300 million patients and 80+ billion medical records provides a robust foundation for commercial insights. The unlimited data access model is particularly disruptive, eliminating traditional usage barriers and potentially accelerating market penetration.
The integration with Veeva's broader ecosystem, including OpenData and Link, creates a compelling value proposition for pharmaceutical companies seeking to optimize their commercial operations. Bayer's adoption and positive feedback validates the platform's effectiveness in identifying new market opportunities. The daily data updates and comprehensive coverage of both retail and specialty brands position Veeva to capture a larger share of the healthcare analytics market.
The strategic importance of this platform expansion lies in its potential to drive recurring revenue growth and deepen client relationships. By offering unlimited access at the brand level, Veeva is likely to see increased adoption across pharmaceutical companies' product portfolios. The platform's ability to support both retail prescriptions and in-office treatments addresses a critical market need for unified data insights.
The expansion of Veeva's data ecosystem strengthens its competitive moat in the life sciences technology sector. With 7+ years of patient history and coverage of 3+ million healthcare providers, the platform offers unmatched depth for commercial analytics. This positions Veeva to capture a larger share of pharmaceutical companies' technology budgets and potentially expand into adjacent markets.
Modern commercial data helps organizations find new patients and HCPs
"We are using Veeva Compass Patient for many of our brands as it helps us find more HCPs and patients than traditional sources," said Sridutta Rao, executive director of commercial data and analytics solutions at Bayer. "Having unlimited access to a complete and modern dataset to generate insights for both retail prescriptions and in-office treatments gives us a better understanding of the entire patient journey."
Compass Patient is licensed for use at the brand level and includes unlimited data access to all patient data. The Compass data network includes more than 300 million patients in the
"Veeva Compass Patient is the next generation of patient data for life sciences," said Peter Stark, executive vice president and general manager of Veeva Compass. "I'm excited to see our customer community growing and driving so much value through our partnership."
Veeva Compass Suite includes Veeva Compass Prescriber, projected prescriptions and procedures at the HCP, HCO, and ZIP level for retail and non-retail products, and Veeva Compass National, projected prescriptions and procedures at the state and national level for retail and non-retail products. Veeva Compass is part of Veeva Data Cloud, the modern, connected data platform for life sciences, which includes Veeva OpenData and Veeva Link.
Additional Information
For more on Veeva Compass, visit: veeva.com/Compass
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-growing-number-of-biopharmas-leverage-veeva-compass-patient-to-improve-commercialization-302329758.html
SOURCE Veeva Systems
FAQ
What is the size of Veeva Compass Patient's data network in 2024?
How does Veeva Compass Patient (VEEV) benefit pharmaceutical companies?
What are the main components of the Veeva Compass Suite?
Which major pharmaceutical company has implemented VEEV's Compass Patient in 2024?
